Member Info for BuenaVista

@B2H, the new patent application will be published at the earliest in September but, if a GB application, may be abandoned in favour of a later World patent application that includes the UK (this is a way to delay the invention being known). It will then be examined for validity and some years later it will be hopefully (near certainty?) be granted (awarded).

Well opti, Avacta currently only has plans to fund AVA6000 in one indication - SGC. Everything else follows from that...

Fantastic news for Avacta's CAR-T program

@Aldebaran, "outline is that CLN will be paid in cash and will be going into sticky hands". Interesting. What will be going into sticky hands?

@Tudor2 here and this in another thread: "‘we continue to engage with third parties’ … I was hoping for something a bit more positive."

What were you expecting? Particularly given that the RNS of 9 June announcing the AGM details stated "All presentation materials will be made available on the website at the end of the day and no new material information will be provided."

As usual, those that attend the AGM will get little hints and nods and winks that verge(!) on material new information but if, like me, you can't or don't want to make it into Peel Hunt's London offices for 8:30, then we'll just have to wait to hear from those that could and did, just like in Alan's days.

Https://www.lse.co.uk/profiles/ralphb1/

Trader. (Note the subtle assumption that there will be a dilutive raise.)

Hamilton1899: LSE member since 25 June 2025, 5 posts, only 4 showing so one was reported and removed.

https://www.lse.co.uk/profiles/hamilton1899/

Byeeeeeeeeeee

Looks like that was a big No from the shareholders then. It was never made clear what she contributed to the business and anyway whatever her role was has now been replaced by the new joiners.

@B2H, I think all it says is that CC regards Yulii as competent and, from experience, someone she can work with rather than taking on a new competent person whose personality may clash with her and her team. A safe appointment, and someone she can count on to support her.

Interesting comment. How do you know that these people are "massive in their respective field"?

@HarChris, enrollment is still continuing: "...the expansion cohort continues to enroll in the indication of salivary gland cancer" so we don't know how many are actually already on the trial and it does take a while until the first scan, so more data, as well as being preferable for stats purposes (qualitatively), is also desirable (quantitatively).

One might even say a very noughty RNS

Is having three joint brokers a good thing? - better than having two?

Https://www.londonstockexchange.com/news-article/AVCT/appointment-of-zeus-capital-as-joint-broker/17111135

All sounds good Bella. But is this Richard Byant a bit like the Grant Naylor concept?😉 Might save us some NED fees!

Timster overcome with nostalgia there

Dr Krishna Komanduri did give a presentation on CAR-T therapy ('Opportunities and challenges for cell and gene therapies for oncology and beyond') at the February 2023 Science Day when he was a member of the Avacta SAB. It seemed a bit out of place to me at the time but I guess it was relevant for AffyXell although AffyXell is (now) working on immunomodulation: autoimmune disease, transplantation rejection (SOT, GVHD), and inflammatory diseases.

http://affyxell.com/en/technology/tech.php

Well there is a world of news about oncology out there; the board could be filled with it every day. As usual, HurstBot did not make any connection between Avacta and this particular bit of news.

Why do you think it is relevant to Avacta?

@Bella, Avacta licensed the pre|CISION technology exclusively from Tufts University in 2018.

No.

Always remember that HurstBot sees the words cancer/tumour/oncology and the algorithm kicks in.

Avacta is committed to commercialising the pre|CISION platform (and Affimers) for use in solid tumours...

Avacta doesn't have the ready cash to take anything into the clinic yet so a wholly different tech area with no in-house expertise?...

CAR-T therapy has limited use in solid tumours (CAR-T therapy in solid tumors: https://www.cell.com/cancer-cell/abstract/S1535-6108(25)00120-5 )...

"While chimeric antigen receptor (CAR) T cell therapy has shown great success in hematologic malignancies, the effectiveness in solid tumors has been limited by several factors, including antigenic heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). In this review, we discuss the advancements made in clinical studies and challenges faced by CAR-T therapy for solid tumors. To enhance CAR-T cell efficacy in solid tumors, we explore strategies such as enhancing T cell persistence and cytotoxicity, targeting multiple antigens, and utilizing innovative allogeneic CAR-T cell manufacturing. Additionally, we highlight the potential benefits of combining CAR-T therapies with immune checkpoint inhibitors and other treatment modalities to overcome TME limitations. We remain optimistic about the future of CAR-T cell therapy in solid tumors, emphasizing the need for continued research to refine therapeutic approaches and address the clinical needs of patients with cancer."